Background and purpose: The purpose of this study was to examine the minimum number
Introduction
Multiple sclerosis (MS) is a chronic autoimmune disease which can result in symptoms such as fatigue, depression, loss of mobility, balance and coordination, and neurological dysfunction [1] [2] [3] . These symptoms have an overall impact on activities of daily living (ADL) and physical functioning [4] , and therefore any treatment and/or intervention which may lessen the impact of these symptoms may improve overall quality of life (QOL) in people with MS [5] .
One such treatment is engaging in regular physical activity (PA) [6] . Recently the numerous health benefits of PA participation, such as reduced risk of sedentary related disease onset [7] , increased muscular strength [7] , and increased psychological wellbeing [8] , have been found among people with MS [9] [10] [11] [12] . However, current research [13] [14] [15] [16] [17] indicates that people with MS are substantially more inactive than their non-diseased counterparts.
The accurate selection of objective measures of PA are vital to a better understanding of PA and MS [18] . PA has previously been defined as "any bodily movement produced by skeletal muscles that result in EE" and therefore accelerometer outputs of both step count and energy expenditure may be useful ways of estimating free living PA [19] . The use of step count as an output is consistent with the use of walking as a primary monitoring outcome of PA in MS research due to its link with disease progression and disability level [20, 21] . Research [22] has found that accelerometers measure both PA and walking mobility in people with MS, whilst also providing an objective measurement outcome sensitive to detecting differences in PA [1] . Furthermore, accelerometer step count has been found to be a reliable measure of PA in people with MS [23] . Additionally, people with MS may use activity modifications, such as a decrease in step count, to conserve EE when performing everyday activities [24] . Therefore, EE is also a parameter of interest when investigating PA levels in people with MS. When measuring step count or EE in a free-living environment the number of days required for monitoring is of importance to ensure a reliable estimate of the variable of interest is collected [18, 23] . People with MS already have significant constraints on everyday living due to MS symptoms; therefore PA measurement should be for as short a possible time as to be accurate, while not overly impacting on the person's life. Whilst a 7-day monitoring period is commonly used to assess PA in people with MS [25] , monitor wearing compliance has ranged from one to seven days [26] . Previous research [23] has investigated the number of days of pedometer monitoring required to accurately predict daily step count in adults with multiple sclerosis, indicating a minimum of 3 days is necessary. However, it was unclear how many participants performed habitual walking behaviour aided or un-aided. People with MS who perform gait unaided are of particular interest as they are typically the targets of PA interventions, and undertake habitual walking behaviour similar to a non-diseased population, whilst concurrently managing the symptoms of MS. Also, whilst previous research [23] recommended a 3-day monitoring period, this cannot be assumed when measuring PA utilising EE as a monitoring outcome, as people with MS adopt alternate EE and step count strategies when performing the same task [24] . In doing so people with MS may slow down the pace at which they move, or in fact move less.
Lastly, in previous research [23] pedometers and accelerometers utilised to measure step count and/or EE were not worn 24 hours a day. This may lead to missed data due to non-wear time. Also, gait behaviour within an MS population can fluctuate from day-to-day, and from one time of a day to another [27] . Therefore, to achieve a thorough reflection of step count and EE in MS population, participants should wear the chosen accelerometer or pedometer for all waking hours. The SenseWear Armband © (SWA) can be worn 24 hours a day and is lightweight and unobtrusive during ADL's. The SWA has been identified to provide adequate step count data in people with MS and a valid estimate of EE during everyday activities [28] .
For this reason, the SWA has achieved many of the recommendations previously set forward for capturing walking behaviour and EE in people with MS [27] .
To this end, the purpose of this study was to investigate the minimum number of days needed to reliably estimate daily step count and EE, using the SWA, in people with MS who walk unaided.
Methods
Data utilised within this study was collected via the "Step It Up" [29] study protocol within a larger randomised controlled trial study. Committee.
Participants and Protocol
Participants completing the "Step It Up" [29] research study were recruited via (1) Whilst numerous outcome measures were recorded within the "
Step It Up" [29] protocol, for this analysis only daily step count and daily EE recorded over a 7-day period preintervention (week 1) were utilised. Daily step count and daily EE data were recorded via the SWA, which participants were asked to wear day and night for a 7-day period. For the current analysis SWA step count and EE data were visually screened post data collection and only participants with 7 valid days of step count and EE data were included. A valid day was a 24 hour period in which there were 10+ hours of awake, recorded SWA activity, criteria previously used within MS populations [31] . Awake hours were identified as the hours between two extended periods of sedentary behaviour (typically 6 to 10 hours), in which a participant displayed both step count and EE data for a minimum of 30 minutes. Therefore, due to SWA failure (n = 4) and participants not having 7 valid days of step count and EE data (n = 38), a total of 26 participants were included in the final analysis (age = 44.5 ± 11.9 years). Participants in the final sample had been diagnosed with MS for 6.5 ± 6.2 years and the majority had relapsing -remitting MS (relapsing -remitting, n = 21; benign, n = 2;
primary progressive, n = 1; secondary progressive, n = 1; unknown, n = 1).
Additionally, the SWA provides two measures of EE. The first EE measure is the conversion of counts, via prediction equations, to metabolic equivalents (METs). The second EE measure is kilocalories per day (kcals per day). Within this study EE was estimated using kcals per day as Coote and O'Dwyer [28] found that kilocalorie estimates provided a more accurate estimate of PA than METS, using the SWA, in people with MS performing ADL's.
Lastly, preceding the main investigation the 7 valid days of step count and EE data collected were categorised by day type (Monday -Sunday) and analysed to investigate if there was a significant difference in daily step count or daily EE due to day type. Within this preceding analysis, 1 of the 26 participants with 7 valid days had two re-occurring days (i.e. Monday twice), due to non-consecutive SWA wear. This participant was therefore omitted from the preceding investigation (n = 25).
Data Analysis
Data analysis methods are similar to those previously used [23, 32, 33] [34] . Explained in detail elsewhere [34] , briefly within the Generalizability Theory firstly we performed an extended two-way repeated measures ANOVA (G-study) in which the amount of variance contributed by each factor (participant and day) and the interaction effect (participant × day) were outlined. Secondly, G-coefficients were calculated using a fully crossed D-study design (participant × day) to derive the minimum number of days needed to calculate a reliable estimate of mean daily step count and mean daily EE. For both ICC values and G-coefficients, following previous literature [23, 32, 33] , a threshold of 0.80 was utilised as the minimum cut-off to calculate the reliable amount of days needed. Lastly, a comparison of methods was assessed by calculating the paired difference of the methods, and the mean of the methods [35] . The criterion method was the mean daily step count and mean daily EE derived from the 7-day period, while the comparison methods were the mean daily step count and mean daily EE values derived from single and multiple day combinations (n = 127 for each parameter). Bland-Altman plots provide mean bias values (criterion -comparison) and 95% confidence intervals (95% CI = ± 1.96 × SD) [36] . These were calculated in both standard units (steps and kcal) and also as a percentage of the criterion and represented in table format.
Results
There were no significant differences for age (p = .521) or years since diagnosis (p = .984)
between the subgroup used in this analysis (n = 26) and the overall group within the '
Step it
Up' research study (n = 68) [29] . Participants daily and weekly mean steps and EE values are outlined in Table 1 . The one-way repeated measures ANOVA indicated no significant difference in mean daily step count (F(6,144) = 1.483, p > 0.05) or mean daily EE (F(6,144) = .987, p > 0.05) across the consecutive 7-day period, regardless of whether they were weekend or week days. Table 2 . G-study results indicated that the majority of the variance in both mean daily step count and mean daily EE were as a result of variance within the participant term (67.5% and 48.8%), whilst the variance between days accounted for minimal variance in both mean daily step count (1.4%) and mean daily EE (11.0%) ( Table 3 ). The remaining variance (31.1% for mean daily step count and 40.2% for mean daily EE) was due to the interaction effect between the participant and day terms and is deemed as non-specific variance. 
Discussion
The aim of this study was to identify the minimum number of days needed to reliably estimate daily step count and daily EE, using the SWA, in an MS population who walk unaided. We found there was no significant difference when examining the effect of day type on daily step count or daily EE therefore used any combination of days from 7 days of 24 hour monitoring in our analysis. The current research indicates a minimum of two days is necessary to reliably estimate daily step count and a minimum of any random 4-day combination is necessary for a reliable estimate of daily EE in this ambulatory sample of people with MS.
The finding that there was no effect of day type on daily step count is supported by previous research [23] which identified that day type had little effect on the reliability of calculating mean daily step count. Almeida, Wasko [37] also found no significant difference in total energy expenditure (TEE) due to day type, in women with rheumatoid arthritis, suggesting that participants did not undertake marked differences in PA during their weekend compared to their weekdays, due to a moderate level of disability. This may support that those with moderate disability due to a chronic disease display relatively consistent levels of PA, as identified by EE, step or activity count, across all days of the week [23] .
Our finding for mean daily step count (8327) confirms the relative inactivity of this population and confirms that the patients in this analysis were representative of the wider MS population with a PDDS ≤ 3. Whilst participants recruited with the "
Step it Up" research study were required to have a sedentary lifestyle, this was defined by the amount of time spent performing moderate to strenuous exercise. As mean daily step count within the current study was similar to that previously reported [25, 38] , it appears people with MS, and a PDDS ≤ 3, may maintain a somewhat active profile, despite not engaging in higher intensity exercise. Mean daily EE calculated via the consecutive and non-consecutive 7-day criterion were also similar to those found when investigating daily TEE in other chronic disease populations such as diabetes and rheumatoid arthritis [37, 39] .
The key investigation in our research was to examine the minimum number of days needed to reliably estimate daily step count and daily EE using the SWA, in people with MS who walk unaided as these are the target of health promoting PA interventions. The current research indicates a minimum of two days is necessary to reliably estimate daily step count. This was supported by both single day ICC values and the single day G -coefficient, as values fell below the recommended 0.80 threshold [33] . This is in agreement with previous research in older adults [40] , however is in contrast to Motl, Zhu [23] who suggested a minimum of three days is required in an MS population and recruited an MS population whom performed gait with or without the use of a cane and utilised a pedometer for data collection. However, the participants in the current study all performed habitual walking behaviour unaided and a multisensory accelerometer based device was utilised for data collection. This may account for the contrast in results found.
For EE, ICC results within the current study indicate a minimum of any random 2-day combination is needed for a reliable estimate of EE. This is supported within a diseased population where ICC values for a random single day compared to the 7-day criterion fell below 0.80, when monitoring daily TEE in women with rheumatoid arthritis [37] . However, on performing the generalisability theory analysis, G -coefficients from combinations less than 4 days fell below 0.80, indicating a minimum of any random 4-day combination is necessary for a reliable estimate of daily EE. The generalisability theory identifies where variance lies within the data, any variance interaction, and this is then factored into Gcoefficient calculation [41] . Also, the generalisability theory has previously been identified as superior to the ICC [41] . Therefore, within the current analysis G-coefficients were given more credence than ICC results and a minimum of any random 4-day combination was regarded as necessary for a reliable estimate of daily EE. Whilst there is limited research investigating the number of days required for a reliable estimate of EE in people with MS, this result is comparable to similar research performed within a healthy population (3-5 days required to calculate a reliable estimate of mean daily EE) [42] , and a population with chronic disease (4 days required to calculate a reliable estimate of mean daily EE) [37] .
Lastly, Bland-Altman results indicated that all combinations of days, bar single day combinations, resulted in a mean bias of ≤ 10 % compared to the criterion 7-day mean, for both step count and EE. When guided by ICC and G-coefficient results selecting a 2-day combination for step count results in a 95% CI range of ± 1943 to ± 3342 steps, compared to the criterion 7-day mean, whilst for EE selecting a 4-day combination results in a 95% CI range of ± 158 to ± 313 kcal, compared to the criterion 7-day mean. Reliable step count devices have been identified to have a 95% CI of ±1801 steps over a three day period in those with a neurological condition [42] and therefore the results represented by the Bland-Altman analysis may be representative of the population.
Study Limitations
Whilst this study contributes significantly to the research questions posed by Motl, Learmonth [18] there are limitations. Firstly, our subgroup (n = 26) is smaller than that previously used in studies investigating PA and step count in people with MS [15, 22, 23] .
Secondly, whilst our sub-group was representative of our larger group (n = 68) in terms of both age and years since diagnosis, it includes only those with minimal to moderate disability (PDDS ≤ 3). Further research should investigate the number of days necessary for a reliable estimate of step count, in people with MS with more activity limitations.
Conclusions
It is vital that we are able to accurately quantify habitual walking behaviour and EE in people with MS, to gain a better understanding of the amount of PA this population undertakes on a daily basis. These results indicate that a minimum of 2 days for step count and a minimum 4 days for EE, regardless of day type, is needed to reliably estimate daily values, using the SWA, in an MS population with unaided walking gait. This may minimise the number of data collection days required in future studies, when researching PA in people with MS utilising a 24-hour activity monitor such as the SWA. This may not only reduce the burden placed upon participants, but also improve adherence within these studies.
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